Latest Imatinib Stories
CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia.
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies.
Oregon Health & Science University today announced that Philip H. and Penny Knight have pledged to give $100 million to the OHSU Cancer Institute.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578).
EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
According to a new study by Cutting Edge Information, tyrosine kinase inhibitors may have five oncology drugs with annual sales over $1 billion by 2013. This list of blockbuster oncology drugs includes Novartis' Gleevec.
EAST HANOVER, N.J., Aug.
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise capacity by a greater percentage than Actelion's Tracleer at 16 weeks, would earn a 48 percent patient share in the treatment of pulmonary arterial hypertension, according to surveyed pulmonologists.
- An imitative word; an onomatopoetic word.